Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic, Inc. (NASDAQ:IMUX) has recently demonstrated strong share price momentum, with its shares up 24.10% in the past five days as of the market open on January 9, 2026. Amid the share price surge, the company's management reviewed 2025 performance and outlined upcoming milestones, issuing a press release on January 7, 2026. The company reflected on progress across both neurologic and gastrointestinal programs, with CEO Dr. Daniel Vitt emphasizing completion of enrollment in the twin Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS). Enrollment randomized 1,121 and 1,100 patients across more than 100 sites in 15 countries. Management highlighted a synchronized top-line readout to assess the therapy's potential to modify disease progression by combining neuroprotective Nurr1 activation with selective DHODH inhibition. The readout is expected by the end of 2026. Meanwhile, durable disability protection was confirmed by
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $8.00 price target on the stock.MarketBeat
- Immunic Highlights 2025 Accomplishments and Upcoming Milestones [Yahoo! Finance]Yahoo! Finance
- Immunic Highlights 2025 Accomplishments and Upcoming MilestonesPR Newswire
- Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunic (NASDAQ:IMUX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 1/6/26 - Form 8-K
- 1/5/26 - Form 8-K
- 12/8/25 - Form SCHEDULE
- IMUX's page on the SEC website